RUNDC1

Summary

RUNDC1 (RUN domain containing 1, HGNC:25418) is a protein-coding gene on chromosome 17q21.31, encoding RUN domain-containing protein 1 (Q96C34). May play a role as p53/TP53 inhibitor and thus may have oncogenic activity.

This gene encodes a protein that contains a RUN (RPIP8, UNC-14 and NESCA) domain and a coiled coil domain. The encoded protein may negatively regulate p53 transcriptional activity. This gene is a potential candidate gene for predisposition to glioma in humans.

Source: NCBI Gene 146923 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 77 total
• MANE Select transcript: NM_173079

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25418
Approved symbol	RUNDC1
Name	RUN domain containing 1
Location	17q21.31
Locus type	gene with protein product
Status	Approved
Aliases	DKFZp761H0421
Ensembl gene	ENSG00000198863
Ensembl biotype	protein_coding
OMIM	619250
Entrez	146923

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 5 protein_coding, 1 retained_intron

ENST00000361677, ENST00000589705, ENST00000590836, ENST00000903300, ENST00000903301, ENST00000954068

RefSeq mRNA: 3 — MANE Select: NM_173079 NM_001321381, NM_001394222, NM_173079

CCDS: CCDS11448

Canonical transcript exons

ENST00000361677 — 5 exons

Exon	Start	End
ENSE00001118527	42987256	42987414
ENSE00001118530	42989341	42989539
ENSE00001212093	42990851	42995142
ENSE00001212104	42980565	42981074
ENSE00003596493	42990317	42990436

Expression profiles

Bgee: expression breadth ubiquitous, 238 present calls, max score 92.23.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.4648 / max 129.1825, expressed in 1784 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
161033	11.4648	1784

Top tissues by expression

248 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
Brodmann (1909) area 23	UBERON:0013554	92.23	gold quality
middle temporal gyrus	UBERON:0002771	91.06	gold quality
bronchial epithelial cell	CL:0002328	88.01	gold quality
bronchus	UBERON:0002185	87.55	gold quality
epithelium of nasopharynx	UBERON:0001951	87.36	gold quality
palpebral conjunctiva	UBERON:0001812	85.74	gold quality
primary visual cortex	UBERON:0002436	84.99	gold quality
kidney epithelium	UBERON:0004819	84.90	silver quality
islet of Langerhans	UBERON:0000006	84.78	gold quality
ileal mucosa	UBERON:0000331	84.76	gold quality
superior frontal gyrus	UBERON:0002661	84.39	gold quality
prefrontal cortex	UBERON:0000451	83.97	gold quality
right uterine tube	UBERON:0001302	83.49	gold quality
epithelial cell of pancreas	CL:0000083	83.39	silver quality
occipital lobe	UBERON:0002021	83.39	gold quality
urethra	UBERON:0000057	83.26	gold quality
nucleus accumbens	UBERON:0001882	82.88	gold quality
frontal cortex	UBERON:0001870	82.79	gold quality
postcentral gyrus	UBERON:0002581	82.58	gold quality
upper arm skin	UBERON:0004263	82.42	gold quality
neocortex	UBERON:0001950	82.26	gold quality
parietal lobe	UBERON:0001872	82.18	gold quality
mucosa of transverse colon	UBERON:0004991	82.06	gold quality
Brodmann (1909) area 9	UBERON:0013540	81.95	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	81.91	gold quality
gastrocnemius	UBERON:0001388	81.78	gold quality
blood	UBERON:0000178	81.70	gold quality
putamen	UBERON:0001874	81.69	gold quality
oviduct epithelium	UBERON:0004804	81.68	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	81.66	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.50

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

64 targeting RUNDC1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-3682-5P	99.93	67.97	1163
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-1273H-5P	99.77	66.32	2471
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-199A-3P	99.75	70.48	929
HSA-MIR-199B-3P	99.75	70.48	929
HSA-MIR-3129-5P	99.75	70.46	914
HSA-MIR-30B-3P	99.70	65.76	2325
HSA-MIR-3689A-3P	99.70	65.73	2306
HSA-MIR-3689B-3P	99.70	65.71	2311
HSA-MIR-3689C	99.70	65.71	2311
HSA-MIR-6779-5P	99.70	65.76	2363
HSA-MIR-875-3P	99.63	69.47	2548
HSA-MIR-802	99.61	67.70	1254
HSA-MIR-3136-3P	99.57	66.59	781
HSA-MIR-7155-3P	99.57	66.48	794
HSA-MIR-4728-3P	99.47	68.94	981
HSA-MIR-4318	99.38	66.94	1505
HSA-MIR-145-3P	99.33	67.66	764
HSA-MIR-504-3P	99.30	67.18	1745
HSA-MIR-6504-3P	99.17	69.31	2891
HSA-MIR-7151-3P	99.04	69.72	2370

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	rundc1	ENSDARG00000091962
mus_musculus	Rundc1	ENSMUSG00000035007
rattus_norvegicus	Rundc1	ENSRNOG00000023768
drosophila_melanogaster	CG3703	FBGN0040348
caenorhabditis_elegans		WBGENE00020572

Protein

Protein identifiers

RUN domain-containing protein 1 — Q96C34 (reviewed: Q96C34)

All UniProt accessions (2): Q96C34, K7EQS2

UniProt curated annotations — full annotation on UniProt →

Function. May play a role as p53/TP53 inhibitor and thus may have oncogenic activity.

Isoforms (2)

UniProt ID	Names	Canonical?
Q96C34-1	1	yes
Q96C34-2	2

RefSeq proteins (3): NP_001308310, NP_001381151, NP_775102* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004012	Run_dom	Domain
IPR037213	Run_dom_sf	Homologous_superfamily
IPR058732	RUNDC1_M	Domain

Pfam: PF02759, PF26030

UniProt features (20 total): modified residue 4, sequence variant 4, region of interest 4, compositionally biased region 3, chain 1, domain 1, splice variant 1, sequence conflict 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96C34-F1	71.42	0.20

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 54, 71, 75, 497

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 68 (showing top): GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, MYOGENIN_Q6, GCANCTGNY_MYOD_Q6, CAGCTG_AP4_Q5, MONNIER_POSTRADIATION_TUMOR_ESCAPE_UP, SRF_Q5_01, SRF_C, GOBP_IN_UTERO_EMBRYONIC_DEVELOPMENT, HIF1_Q3, GOBP_EMBRYO_DEVELOPMENT, ACEVEDO_LIVER_CANCER_UP, TGGAAA_NFAT_Q4_01, RYTGCNWTGGNR_UNKNOWN, MEF2_03, LU_EZH2_TARGETS_DN

GO Biological Process (1): in utero embryonic development (GO:0001701)

GO Molecular Function (0):

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
chordate embryonic development	1

Protein interactions and networks

STRING

332 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RUNDC1	CCDC186	Q7Z3E2	546
RUNDC1	VPS50	Q96JG6	541
RUNDC1	EIPR1	Q53HC9	496
RUNDC1	VPS54	Q9P1Q0	485
RUNDC1	VPS51	Q9UID3	453
RUNDC1	TMF1	P82094	451
RUNDC1	PTGES3L	E9PB15	442
RUNDC1	VPS53	Q5VIR6	426
RUNDC1	RAB2A	P08886	420
RUNDC1	LRRC46	Q96FV0	411
RUNDC1	ICA1	P78506	406
RUNDC1	CHCHD5	Q9BSY4	396
RUNDC1	PGAP1	Q75T13	396
RUNDC1	VPS52	Q8N1B4	396
RUNDC1	DYM	Q7RTS9	394

IntAct

11 interactions, top by confidence:

A	B	Type	Score
ENPP6	SCAMP1	psi-mi:“MI:0914”(association)	0.640
INSYN2A	CHUK	psi-mi:“MI:0914”(association)	0.530
ALOX5	DDHD2	psi-mi:“MI:0914”(association)	0.530
TNKS	RUNDC1	psi-mi:“MI:0407”(direct interaction)	0.440
EFNA4	NBAS	psi-mi:“MI:0914”(association)	0.350
DUSP16	MEIOC	psi-mi:“MI:0914”(association)	0.350
CCDC183	PCNT	psi-mi:“MI:0914”(association)	0.350
KCNE3	TMEM131L	psi-mi:“MI:0914”(association)	0.350
EEF1AKMT3	SMCHD1	psi-mi:“MI:0914”(association)	0.350
NIPAL3	ILVBL	psi-mi:“MI:0914”(association)	0.350

BioGRID (30): RUNDC1 (Affinity Capture-MS), RUNDC1 (Affinity Capture-MS), RUNDC1 (Affinity Capture-MS), RUNDC1 (Affinity Capture-MS), RUNDC1 (Affinity Capture-MS), RUNDC1 (Affinity Capture-MS), RUNDC1 (Affinity Capture-MS), RUNDC1 (Affinity Capture-MS), RUNDC1 (Proximity Label-MS), RUNDC1 (Proximity Label-MS), RUNDC1 (Proximity Label-MS), RUNDC1 (Proximity Label-MS), RUNDC1 (Proximity Label-MS), RUNDC1 (Proximity Label-MS), RUNDC1 (Proximity Label-MS)

ESM2 similar proteins: A0JNT9, A0JPP8, A1X157, O15169, O75145, O75335, P39880, P60469, Q07DZ5, Q08CF3, Q08E13, Q09YM8, Q2M1P5, Q2QLG9, Q2VUH7, Q32PN7, Q3TMW1, Q3UHC7, Q3UIL6, Q3UIW5, Q3UJV1, Q5DU25, Q5FWS6, Q5JU85, Q5PRF9, Q5XI59, Q5ZJ07, Q674X7, Q68UI8, Q69ZS8, Q6IPM2, Q6NZT2, Q6P402, Q6P730, Q6ZP65, Q80XS6, Q80Y83, Q8JZP9, Q8K1S6, Q8R4R9

Diamond homologs: A3KGB4, A5D7F8, A6H8I2, A6QP29, B1AVH7, B1V8A0, B5DFA1, D2H0G5, E2RP94, M0R4F8, O35179, O35180, O35964, O42287, O43048, O43307, O75791, O88811, O89100, O95759, P10569, P19706, P38753, P48566, P53258, P58802, P62993, P62994, P70297, Q09830, Q0IIM8, Q0U6X7, Q12317, Q14155, Q15811, Q1E878, Q28CB1, Q28E95, Q2KI13, Q2KJA1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

77 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	66
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

676 predictions. Top by Δscore:

Variant	Effect	Δscore
17:42987248:T:TA	acceptor_gain	1.0000
17:42987254:A:AG	acceptor_gain	1.0000
17:42987254:AG:A	acceptor_loss	1.0000
17:42987254:AGAGT:A	acceptor_gain	1.0000
17:42987255:G:GC	acceptor_gain	1.0000
17:42987255:GA:G	acceptor_gain	1.0000
17:42987255:GAGT:G	acceptor_gain	1.0000
17:42987255:GAGTG:G	acceptor_gain	1.0000
17:42987411:GCGG:G	donor_gain	1.0000
17:42987413:GG:G	donor_gain	1.0000
17:42987414:GG:G	donor_gain	1.0000
17:42987415:G:GG	donor_gain	1.0000
17:42987416:T:G	donor_loss	1.0000
17:42989337:GTAGG:G	acceptor_loss	1.0000
17:42989338:TAG:T	acceptor_loss	1.0000
17:42989339:A:AT	acceptor_loss	1.0000
17:42989340:G:GA	acceptor_loss	1.0000
17:42989536:CAAG:C	donor_loss	1.0000
17:42989538:AGG:A	donor_loss	1.0000
17:42989540:GTTAG:G	donor_loss	1.0000
17:42989541:T:A	donor_loss	1.0000
17:42990302:A:AG	acceptor_gain	1.0000
17:42990303:A:G	acceptor_gain	1.0000
17:42990308:T:A	acceptor_gain	1.0000
17:42990313:CCAG:C	acceptor_loss	1.0000
17:42990315:A:AG	acceptor_gain	1.0000
17:42990315:AGAT:A	acceptor_gain	1.0000
17:42990316:G:GA	acceptor_gain	1.0000
17:42990316:GA:G	acceptor_gain	1.0000
17:42990316:GAT:G	acceptor_gain	1.0000

AlphaMissense

3956 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
17:42989492:T:C	L270P	1.000
17:42987323:T:C	L189P	0.999
17:42989513:T:C	L277P	0.999
17:42991291:T:A	W473R	0.999
17:42991291:T:C	W473R	0.999
17:42991534:T:A	W554R	0.999
17:42991534:T:C	W554R	0.999
17:42991711:T:C	F613L	0.999
17:42991713:T:A	F613L	0.999
17:42991713:T:G	F613L	0.999
17:42987335:T:C	L193P	0.998
17:42989521:T:C	F280L	0.998
17:42989523:T:A	F280L	0.998
17:42989523:T:G	F280L	0.998
17:42980899:T:C	L108P	0.997
17:42980953:T:C	L126P	0.997
17:42987344:T:C	L196P	0.997
17:42989510:A:C	D276A	0.997
17:42989510:A:G	D276G	0.997
17:42989513:T:A	L277H	0.997
17:42989522:T:C	F280S	0.997
17:42991184:T:C	L437P	0.997
17:42991293:G:C	W473C	0.997
17:42991293:G:T	W473C	0.997
17:42991372:T:C	F500L	0.997
17:42991374:C:A	F500L	0.997
17:42991374:C:G	F500L	0.997
17:42991511:T:C	L546P	0.997
17:42991591:A:C	S573R	0.997
17:42991593:C:A	S573R	0.997

dbSNP variants (sampled 300 via entrez): RS1000245006 (17:42983944 A>G), RS1000443307 (17:42992837 G>T), RS1000585429 (17:42985463 G>A,C), RS1000617736 (17:42988473 G>A,C), RS1000774878 (17:42988799 C>T), RS1000877143 (17:42991892 A>C,G), RS1001289871 (17:42994029 T>C), RS1001429904 (17:42994339 A>G), RS1001762427 (17:42981583 C>T), RS1002470277 (17:42980203 T>C,G), RS1002535036 (17:42989959 T>C), RS1002652749 (17:42989758 C>G), RS1002709642 (17:42985534 T>C), RS1002835438 (17:42987973 A>G), RS1002887410 (17:42987541 A>G)

Disease associations

OMIM: gene MIM:619250 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): prostate cancer (MONDO:0008315)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	increases phosphorylation	1
potassium chromate(VI)	increases expression	1
beta-methylcholine	affects expression	1
avobenzone	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
torcetrapib	increases expression	1
ICG 001	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	affects methylation	1
Caffeine	decreases phosphorylation	1
Doxorubicin	decreases expression	1
Formaldehyde	decreases expression	1
Plant Extracts	affects cotreatment, increases expression	1
Smoke	decreases expression	1
Urethane	decreases expression	1
Valproic Acid	increases methylation	1
Aflatoxin B1	increases methylation	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer